Brain and spinal cord atrophy in multiple sclerosis

Neuroimaging Clinics of North America

Volumn 10, Issue 4, 2000, Pages 753-769

  Simon, J H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ATROPHY; BRAIN STEM; CEREBELLUM ATROPHY; CORPUS CALLOSUM; HIGH RISK PATIENT; HUMAN; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; REVIEW; SPINAL CORD ATROPHY;

ATROPHY; AXONS; BRAIN; CEREBRAL VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MYELIN SHEATH; PROGNOSIS; SPINAL CORD;

EID: 0034446552     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. The morbid anatomy of the demyelinative diseases
2. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis
3. Brain MRI lesions and atrophy are related to depression in multiple sclerosis
4. Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study
5. Relapsing-remitting multiple sclerosis: Sequential enhanced MR imaging vs. clinical findings in determining disease activity
6. Corpus callosum in multiple sclerosis
7. The long-standing MS lesion: A quantitative MRI and electron microscopic study
8. Quantitative volumetric analysis of brain MR: Normative database spanning 5 decades of life
9. Detection of ventricular enlargement in patients at the earliest clinical stage of MS
10. The distribution of plaques in the cerebrum in multiple sclerosis
11. Inflammatory central nervous system: Correlation of magnetic resonance imaging findings with lesion pathology
12. Computerized tomography of brain and optic nerve in multiple sclerosis: Observations in 100 patients, including serial studies in 16
13. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
14. Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis
15. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis
16. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss
17. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis
18. Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis
19. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis
20. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
21. Axonal damage in acute multiple sclerosis lesions
22. A spinal cord MRI study of benign and secondary progressive multiple sclerosis
23. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis
24. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis
25. Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis
26. Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI
27. Electroencephalographic and pneumoencephalographic studies of multiple sclerosis
28. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment
29. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
30. Macrophage responses and myelin clearance during Wallerian degeneration: Relevance to immune-mediated demyelination
31. Gender differences in age effect on brain atrophy measured by magnetic resonance imaging
32. Computer tomography of the cerebrum in multiple sclerosis
33. Computerized tomography in the diagnostic evaluation of multiple sclerosis
34. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis
35. Magnetic resonance imaging of spinal cord lesions in multiple sclerosis
36. Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis
37. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States
38. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
39. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
40. Brain atrophy as a surrogate marker in MS: Faster, simpler, better?
41. MRI dynamics of brain and spinal cord in progressive multiple sclerosis
42. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis
43. Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: Potential outcome measures for future multiple sclerosis 'prevention' trials
44. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis
45. Wallerian degeneration after cerebral infarction: Evaluation with sequential MR imaging
46. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis
47. Pneumoencephalography in multiple sclerosis
48. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis
49. Progressive cerebral atrophy in multiple sclerosis: A serial MRI study
50. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
51. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis
52. The neuropathology of multiple sclerosis
53. Magnetization transfer ratio of the spinal cord in multiple sclerosis: Relationship to atrophy and neurologic disability
54. Patterns of spinal cord atrophy by metrizamide CT
55. Rachelle Fishman-Matthew Moore Lecture: The pathological and clinical dynamics of multiple sclerosis
56. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis
57. Determinants of brain atrophy in relapsing multiple sclerosis
58. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
59. The role of magnetic resonance techniques in understanding and managing multiple sclerosis
60. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of MS: A five year follow-up study
61. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: A 10 year follow-up
62. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
63. Brain atrophy in relapsing-remitting multiple sclerosis: Relationship with 'black holes,' disease duration and clinical disability
64. Functional and magnetic resonance imaging correlates of callosal involvement in multiple sclerosis
65. Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis
66. Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis
67. The neuropathology of multiple sclerosis
68. The fine structure of chronically active multiple sclerosis plaques
69. Demyelinating lesions
70. Neuropsychology of multiple sclerosis
71. Cerebral disconnection in multiple sclerosis: Relationship to atrophy of the corpus callosum
72. Chronic progressive multiple sclerosis: Relationship between cerebral ventricular size and neuropsychological impairment
73. Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis
74. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
75. Callosal disconnection in multiple sclerosis
76. From enhancing lesions to brain atrophy in relapsing MS
77. Magnetic resonance imaging in the diagnosis of multiple sclerosis: Elucidation of disease course, and determining prognosis
78. Corpus callosum and subcallosal-periventricular lesions in multiple sclerosis: Detection with MR
79. A longitudinal study of brain atrophy in relapsing multiple sclerosis
80. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis
81. Wallerian degeneration pattern in patients at risk for MS
82. A longitudinal study of T1-hypointense lesions in relapsing MS: Results from the MSCRG trial of interferon beta-1a
83. Assessment of optic nerve damage in multiple sclerosis using magnetic resonance imaging
84. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging
85. Spinal cord atrophy and disability in MS: A longitudinal study
86. One year follow up study of primary and transitional progressive multiple sclerosis
87. Primary and transitional progressive MS: A clinical and MRI cross-sectional study
88. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters
89. Primary progressive multiple sclerosis
90. A magnetization transfer histogram study of normal-appearing brain tissue in MS
91. Axonal transection in the lesions of multiple sclerosis
92. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
93. Accumulation of hypointense lesions ("black holes") on T1 spin echo MRI correlates with disease progression in multiple sclerosis
94. Correlation of dementia, neuropsychological and MRI findings in multiple sclerosis
95. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
96. Pathology of multiple sclerosis
97. Outcomes assessment in multiple sclerosis clinical trials: A critical analysis
98. Linomide in relapsing and secondary progressive MS: Part II: MRI results
99. Optic neuritis: Swelling and atrophy